CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could less radiation be enough? new study tests kinder treatment for HPV throat cancer
Disease control OngoingThis study looks at whether a lower dose of radiation combined with the immunotherapy drug nivolumab can control early-stage HPV-positive throat cancer as well as the standard higher-dose radiation plus chemotherapy (cisplatin). The trial includes 384 non-smoking patients with ea…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Immunotherapy after standard treatment may keep HPV throat cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after standard chemo-radiation helps people with HPV-positive throat cancer live longer and stay cancer-free longer. About 636 adults with intermediate-risk, locally advanced disease will either receive nivolumab or…
Matched conditions: CLINICAL STAGE II HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC